The Claim

Released a comprehensive review of so-called “gender-affirming care,” finding no strong medical or scientific evidence exists to support the treatment’s irreversible effects.

The Claim, Unpacked

What is literally being asserted?

Two claims: (1) the administration released a “comprehensive review” of gender-affirming care, and (2) this review found “no strong medical or scientific evidence” supporting “the treatment’s irreversible effects.” The phrasing is ambiguous — it could mean the review found no evidence supporting the use of treatments that have irreversible effects, or no evidence that the treatments have irreversible effects. Context makes the former reading more likely: the administration is claiming there is no good evidence that these treatments work.

What is being implied but not asserted?

The phrase “so-called” before “gender-affirming care” performs significant rhetorical work, implying the medical terminology used by the American Academy of Pediatrics, the Endocrine Society, the American Medical Association, and dozens of other professional organizations is itself illegitimate. The claim implies this was an independent, objective scientific review rather than a politically directed exercise that reached a predetermined conclusion. It implies the finding of “no strong evidence” represents scientific consensus rather than the minority view of authors selected for their opposition to gender-affirming care.

What is conspicuously absent?

That this review was mandated by the very executive order (EO 14187) that had already declared the policy conclusion the review was supposed to evaluate. That the authors’ identities were concealed for six months, and when revealed, included individuals affiliated with organizations classified as anti-LGBTQ by the SPLC. That the AAP, AMA, Endocrine Society, and American Psychological Association all rejected the report’s conclusions and methodology. That the Cass Review — the most significant international evidence reassessment — recommended individualized assessment and clinical trials, not the blanket prohibition the administration imposed. And most conspicuously absent: that item 224 on this same list already claimed credit for ending gender-affirming care for minors based on, among other mechanisms, this very report.

Padding Analysis: Repackaging the HHS Report Already Credited in Item 224

This item is padding of item 224. Item 224 claims: “Ended federal funding for chemical and surgical gender procedures for minors through executive action and regulatory enforcement, driving the end to these harmful procedures for minors at health systems across the country.” The HHS evidence review described in item 288 was the 90-day literature review mandated by EO 14187 — the same executive order credited in item 224 as the foundation for the policy. Item 224 already addresses the HHS report’s conclusions, its contested authorship, its rejection by major medical organizations, and its role in the broader campaign to restrict gender-affirming care. Item 288 extracts one component of the item 224 policy package — the evidence review — and presents it as a separate “win.” This is a single policy initiative counted twice.

Evidence Assessment

Established Facts

HHS published “Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices” on May 1, 2025, as directed by EO 14187. ¹ The executive order, signed January 28, 2025, directed HHS to publish a “review of existing literature regarding the health effects of pediatric gender transition” within 90 days. HHS produced a roughly 400-page document concluding that evidence for gender-affirming medical interventions (puberty blockers, hormones, surgery) was “insufficient” and that psychotherapy — including “exploratory therapy” — should be the preferred treatment approach. The report was not published through any medical journal or standard peer-review process. A “finalized” version with peer review comments was released November 19, 2025.

The report’s authors were concealed for six months, and when revealed, included individuals affiliated with anti-LGBTQ organizations. ² At publication, HHS identified the authors only as “eight scholars including doctors, ethicists and a methodologist who represent a wide range of political viewpoints,” claiming names were withheld to protect the “integrity” of post-publication peer review. On November 19, 2025, HHS disclosed the authors: Evgenia Abbruzzese (Society for Evidence-Based Gender Medicine), Alex Byrne (MIT philosopher), Michael K. Laidlaw (endocrinologist and critic of gender-affirming care), Kathleen McDeavitt (Baylor College of Medicine), and Leor Sapir (Manhattan Institute for Policy Research), among others. Multiple authors are affiliated with organizations classified as anti-LGBTQ by the SPLC, including the Alliance Defending Freedom, the American College of Pediatricians (a small advocacy group distinct from the AAP), and the Society for Evidence-Based Gender Medicine. The American Psychological Association stated that withholding author identities “undermine[d] scientific rigor and contradict[ed] standards for evidence-based policymaking.”

Major medical organizations rejected the report’s conclusions and methodology. ³ The American Academy of Pediatrics stated the report “misrepresents the current medical consensus and fails to reflect the realities of pediatric care,” and noted that “AAP was not consulted in the development of this report.” The Endocrine Society reaffirmed its clinical guideline — based on 260+ studies — supporting access to gender-affirming care for transgender and gender-diverse youth. WPATH and USPATH jointly stated the report “misrepresents existing research and disregards the expertise of professionals who have been working with transgender and gender-diverse youth for decades.” A peer-reviewed critique published in the Journal of Adolescent Health (September 2025) by researchers from Children’s Hospital of Philadelphia, Northwestern, and Yale identified methodological flaws. A separate peer-reviewed article in Sexuality Research and Social Policy disputed the report’s scientific integrity. Science magazine (AAAS) reported that multiple researchers criticized both the methodology and the 90-day timeline as inadequate for a rigorous systematic review.

The report was directed by an executive order that had already stated the policy conclusion. ⁴ EO 14187 declared as its policy that the United States “will not fund, sponsor, promote, assist, or support the so-called ‘transition’ of a child from one sex to another.” It directed HHS to “take all appropriate actions to end the chemical and surgical mutilation of children” and to publish the evidence review — embedding the conclusion in the order that mandated the review. The review was not an independent inquiry; it was a deliverable within a policy directive that presupposed its findings. This is the structural inverse of evidence-based policymaking: policy-based evidence selection.

Strong Inferences

The report’s recommendation of “exploratory psychotherapy” is functionally similar to conversion therapy, despite the report’s denial. ⁵ The report promotes “exploratory therapy” — described in part as helping minors “come to terms with their bodies” — as an alternative to gender-affirming medical care. Critics, including Arjee Restar of Yale University, characterized this as echoing “the same ideology and pathologizing practices that underpinned past conversion therapy practices.” The Cass Review, which the HHS report frequently cites, explicitly stated that “no LGBTQ+ group should be subjected to conversion practice.” The distinction the HHS report draws between “exploratory therapy” and conversion therapy relies on a definitional boundary that medical professionals treating gender-diverse youth have disputed.

The claim that “no strong evidence” exists overstates what even cautious international reviews found. ⁶ The Cass Review found “weak evidence” for puberty blockers specifically and recommended they be restricted to clinical trials — but it did not conclude that there was “no” evidence supporting gender-affirming care broadly. It recommended individualized, holistic assessment and cautious provision of hormones for 16-17 year olds. Sweden’s Karolinska Institute restricted blockers to research settings but continued to provide hormones under controlled conditions. Finland restricted treatment to exceptional cases with thorough psychiatric evaluation. None of these international bodies recommended blanket prohibition or concluded that “no strong evidence” exists for all gender-affirming treatment. The HHS report’s conclusion is maximalist where the international evidence is cautious.

What the Evidence Shows

The factual core of the claim is accurate in the narrowest sense: the administration did release a review document, and that document did conclude that evidence was insufficient. But presenting this as a neutral, “comprehensive” scientific review mischaracterizes what happened at every level.

The review was mandated by an executive order that had already declared its policy conclusion. It was authored by individuals selected for their prior opposition to gender-affirming care, whose identities were concealed for six months in violation of standard scientific transparency norms. Its conclusion — that “no strong evidence” supports these treatments — was rejected by the American Academy of Pediatrics (67,000 members), the Endocrine Society, the AMA, the American Psychological Association, and WPATH. Peer-reviewed critiques in the Journal of Adolescent Health and Sexuality Research and Social Policy identified methodological flaws. Researchers quoted in Science magazine questioned whether a 90-day timeline was adequate for a rigorous systematic review.

The claim is also straightforward padding. Item 224 on this same list already credits the administration with “ending federal funding for chemical and surgical gender procedures for minors through executive action and regulatory enforcement.” The HHS evidence review was one component of the EO 14187 implementation that item 224 addresses in detail. Listing it separately inflates the win count.

It is worth steel-manning the genuine scientific debate the report sits within. The international evidence base for pediatric gender-affirming care — particularly puberty blockers — is weaker than it was characterized circa 2020, and the Cass Review, Nordic country reassessments, and the AMA’s own February 2026 update all reflect legitimate caution about surgical interventions in minors. But the administration’s HHS report does not engage with this nuanced picture. It takes the legitimate caution of the Cass Review and weaponizes it into a maximalist conclusion that the international reviewers themselves did not reach, delivered through a process that violated basic principles of scientific transparency and independence.

The Bottom Line

This is padding of item 224. The “comprehensive review” referenced here is the HHS report mandated by EO 14187 — the same executive order already credited in item 224 as the foundation for the administration’s gender-affirming care restrictions. The report itself, while real, was produced on a politically directed 90-day timeline by concealed authors later revealed to be affiliated with anti-LGBTQ organizations, and its conclusions were rejected by the AAP, AMA, Endocrine Society, and American Psychological Association. Its claim of finding “no strong evidence” overstates what even cautious international reviews concluded: the Cass Review and Nordic reassessments recommended greater caution and individualized assessment, not blanket prohibition. The administration produced a policy-confirming document, credited it as a win in item 224, and then listed it again here as a separate achievement. One initiative, two line items.

Footnotes

1. HHS Office of Population Affairs, “Gender Dysphoria Report” (published May 1, 2025; finalized November 19, 2025). https://opa.hhs.gov/gender-dysphoria-report ; HHS Press Release, “HHS Releases Peer-Reviewed Report Discrediting Pediatric Sex-Rejecting Procedures” (November 19, 2025). https://www.hhs.gov/press-room/hhs-releases-peer-reviewed-report-discrediting-pediatric-sex-rejecting-procedures.html ; Executive Order 14187, Section 4(b), directing 90-day evidence review. https://www.whitehouse.gov/presidential-actions/2025/01/protecting-children-from-chemical-and-surgical-mutilation/ ↩

2. STAT News, “HHS names authors and releases peer review comments for gender dysphoria report” (November 19, 2025). https://www.statnews.com/2025/11/19/hhs-gender-affirming-care-report-authors-named/ ; NPR, “HHS report critiques health care for transgender children and hides authors’ names” (May 1, 2025). https://www.npr.org/sections/shots-health-news/2025/05/01/nx-s1-5383599/transgender-gender-affirming-care-trump-hhs ; Wikipedia, “Trump administration HHS gender dysphoria report.” https://en.wikipedia.org/wiki/Trump_administration_HHS_gender_dysphoria_report ↩

3. AAP News, “AAP speaks out against HHS report on gender dysphoria.” https://publications.aap.org/aapnews/news/32145/AAP-speaks-out-against-HHS-report-on-gender ; Science/AAAS, “Researchers slam HHS report on gender-affirming care for youth.” https://www.science.org/content/article/researchers-slam-hhs-report-gender-affirming-care-youth ; Journal of Adolescent Health, “A Critical Scientific Appraisal of the Health and Human Services Report on Pediatric Gender Dysphoria” (September 2025). https://www.jahonline.org/article/S1054-139X(25)00246-0/abstract ; Sexuality Research and Social Policy, “Scientific Integrity and Pediatric Gender Healthcare: Disputing the HHS Review” (2025). https://link.springer.com/article/10.1007/s13178-025-01221-5 ↩

4. Executive Order 14187, “Protecting Children from Chemical and Surgical Mutilation” (January 28, 2025), Section 2 (Policy) and Section 4(b) (evidence review directive). https://www.whitehouse.gov/presidential-actions/2025/01/protecting-children-from-chemical-and-surgical-mutilation/ ; White House Fact Sheet, “Report to the President on Protecting Children from Surgical and Chemical Mutilation Executive Summary” (April 2025). https://www.whitehouse.gov/fact-sheets/2025/04/report-to-the-president-on-protecting-children-from-surgical-and-chemical-mutilation-executive-summary/ ↩

5. KFF, “Examining HHS Report on Pediatric Gender Dysphoria and Gender Conversion Efforts.” https://www.kff.org/lgbtq/u-s-department-of-health-and-human-services-report-on-pediatric-gender-dysphoria-and-gender-conversion-efforts/ ; TIME, “HHS Report Urges ‘Exploratory Therapy’ for Transgender Youth.” https://time.com/7281894/new-hhs-report-exploratory-therapy-transgender-youth/ ↩

6. Cass Review Final Report (April 2024), summarized in Wikipedia. https://en.wikipedia.org/wiki/Cass_Review ; KFF, “Examining HHS Report on Pediatric Gender Dysphoria and Gender Conversion Efforts.” https://www.kff.org/lgbtq/u-s-department-of-health-and-human-services-report-on-pediatric-gender-dysphoria-and-gender-conversion-efforts/ ↩